Skip to main content

Table 2 Univariate analysis of survival less than or equal to 24 months vs. greater than 24 months

From: Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

Characteristics

 

N

≤24 months

> 24 months

OR (95% CI)

p-value

Age (years)

Mean (standard deviation)

505

64.5 (12.7)

64.19 (11.9)

0.99 (0.98–1.01)

0.782

Sex

Male

198

101 (46.3%)

97 (33.8%)

1.69 (1.17–2.42)

0.004

 

Female

307

117 (56.7%)

190 (66.2%)

  

ECOG *

0–1

432

163 (75.1%)

269 (93.7%)

0.2 (0.11–0.35)

< 0.001

 

2–4

72

54 (24.9%)

18 (6.3%)

  

Weight loss *

Yes

102

53 (33.3%)

51 (22.9%)

0.59 (0.37–0.93)

0.024

Smoking history *

Never smoker

273

106 (49.3%)

163 (57.6%)

0.80 (0.54–1.19) 0.51 (1.20–1.96)

0.060

Ex-smoker

168

75 (34.9%)

93 (32.9%)

 

Current smoker

61

34 (15.8%)

27 (9.5%)

 

Lives with a smoker *

Yes

43

18 (28.1%)

25 (22.9%)

0.76 (0.37–1.53)

0.446

Distribution of stages

Stage IIIB

30

9 (4.1%)

21 (7.3%)

0.54 (0.24–1.21)

0.133

Stage IV

475

209 (95.9%)

266 (92.7%)

 

Type of mutations**

Exon 19 deletion

279

109 (50.0%)

170 (59.2%)

1.45 (1.01–2.07)

0.039

L858R

143

59 (27.1%)

84 (29.3%)

1.11 (0.75–1.65)

0.586

 

Exon 20 insertion

24

16 (7.3%)

8 (2.8%)

0.36 (0.15–0.86)

0.020

 

G719X

17

10 (4.6%)

7 (2.4%)

0.52 (0.19–1.39)

0.141

 

S768I

10

5 (2.3%)

5 (1.7%)

0.75 (0.21–2.64)

0.660

 

L861Q

2

1 (0.5%)

1 (0.4%)

0.75 (0.05–12.19)

1.000

 

Unknown

20

12 (5.5%)

8 (2.8%)

0.49 (0.19–1.22)

0.121

 

T790M

146

30 (13.8%)

116 (40.4%)

4.25 (2.70–6.67)

< 0.001

 

T790M + Del19

83

12 (5.5%)

71 (24.7%)

5.64 (2.97–10.71)

< 0.001

 

T790M + L858R

38

6 (2.7%)

32 (11.1%)

4.43 (1.81–10.80)

< 0.001

N° de metastatic sites

Average (P25; P75)

505

2 (1; 3)

1 (1; 3)

0.75 (0.66–0.86)

< 0.001

N° of patients with metastatic site at diagnosis **

Bone

208

100 (45.9%)

108 (37.6%)

0.71 (0.50–1.01)

0.062

Lung

190

84 (38.5%)

106 (36.9%)

0.93 (0.65–1.34)

0.713

Pleural effusion

136

64 (29.4%)

72 (25.1%)

0.80 (0.54–1.19)

0.284

CNS

85

51 (23.4%)

34 (11.9%)

0.44 (0.27–0.71)

0.001

 

Liver

73

44 (20.2%)

29 (10.1%)

0.44 (0.27–0.74)

0.001

 

Adrenal glands

45

31 (14.2%)

14 (4.9%)

0.31 (0.16–0.60)

< 0.001

 

Pericardial effusion

11

4 (1.8%)

7 (2.4%)

1.33 (0.38–4.62)

0.445

  1. * Patients do not add up to the exact total (n 505) for some variables due to lack of data
  2. ** Patients may add up to more than the total (n 505) since a patient may have one or more mutations or metastatic sites